THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Cargo Therapeutics, a Bay Area biotech company, announced in a filing Tuesday that it is discontinuing its drug development ...

Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Thursday, Reuters reported that Martin Holst Lange, head of development ... other conditions. The Phase II trial, launched in May 2024 and currently recruiting globally, is studying the effectiveness ...